A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Clinical trial NCT02508207 · COMPLETED
Trial details
- NCT number
- NCT02508207
- Sponsor
- Vertex Pharmaceuticals Incorporated
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-02-01
- Primary completion
- 2017-06-01
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.